title: Determination of advanced glycation end-products and antibodies against them (anti-CML and anti-CEL) in the serum of Graves' orbitopathy patients before and after methylprednisolone treatment.
abstract: BACKGROUND
  The glycation process is a non-enzymatic modification of proteins occurring due to the reactions of reductive carbohydrates. The glycated residues lose their biological functions, and their removal process is ineffective. They accumulate, and as a result they cause an immunological response. The aim of this study was a determination of the concentrations of advanced glycation end-products and antibodies against carboxymethyl lysine (anti-CML) and carboxyethyl lysine (anti-CEL) in the sera of Graves' orbitopathy patients.
  
  
  METHODS
  The study group were patients from the Division of Endocrinology of the Medical University of Silesia (n = 25) suffering from Graves' orbitopathy. The concentration of AGE-peptides using flow spectrofluorimetry method, and anti-CML and anti-CEL IgG antibodies using immunoenzymatic technique (ELISA), were measured in patients sera before and after methylprednisolone treatment.
  
  
  RESULTS
  In sera of the study group the concentrations of AGE-peptides and anti-CML were significantly lower before and after treatment in comparison to the control group (p < 0.05). Mean values of anti-CEL concentrations were comparable (at both phases of treatment) with the value observed in the control group. After treatment the concentrations of AGE-peptides and anti-CEL significantly decreased (p < 0.05); however, the concentration of anti-CML was also lower but the observed change was not significant (p > 0.05).
  
  
  CONCLUSIONS
  In the course of Graves' orbitopathy the glycation process is disturbed. The treatment modifies significantly the process by lowering the concentration of advanced glycation end-products and suppressing the immune response to them. (Endokrynol Pol 2016; 67 (4): 383-389).
authors.affiliation: Division of Endocrinology, Medical University of Silesia, Katowice, Poland. januszstr@op.pl.
authors.forename: Janusz
authors.initials: J
authors.lastname: Strzelczyk
authors.forename: Magdalena
authors.initials: M
authors.lastname: Szumska
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Damasiewicz-Bodzek
authors.forename: Anna
authors.initials: A
authors.lastname: Krywult
authors.forename: Michał
authors.initials: M
authors.lastname: Długaszek
authors.forename: Justyna
authors.initials: J
authors.lastname: Czubilińska
authors.forename: Kaja
authors.initials: K
authors.lastname: Gawlik
authors.forename: Konrad
authors.initials: K
authors.lastname: Synowiec
authors.forename: Krystyna
authors.initials: K
authors.lastname: Tyrpień-Golder
authors.forename: Karolina
authors.initials: K
authors.lastname: Poczkaj
authors.forename: Beata
authors.initials: B
authors.lastname: Kos-Kudła
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000187:drug effects*; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology; D049970:Graves Ophthalmopathy / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000276:immunology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D017127:Glycation End Products, Advanced; C000612723:N(6)-carboxyethyllysine; C048496:N(6)-carboxymethyllysine; D008239:Lysine; D008775:Methylprednisolone
keywords: Graves’ orbitiopathy; anti-CEL; anti-CML; methylprednisolone treatment